Characterization of Invasive Neisseria meningitidis from Atlantic Canada, 2009 To 2013: With Special Reference to the Nonpolysaccharide Vaccine Targets (Pora, Factor H Binding Protein, Neisseria Heparin-Binding Antigen and Neisseria Adhesin A)
| Autor: | GJ German, Tim Mailman, Dennis K. S. Law, Robert Needle, Raymond S. W. Tsang, RR Gad |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Microbiology (medical)
Infectious and parasitic diseases RC109-216 medicine.disease_cause Microbiology 03 medical and health sciences 0302 clinical medicine Antigen Conjugate vaccine medicine 030212 general & internal medicine 0303 health sciences biology 030306 microbiology Binding protein Neisseria meningitidis Atlantic Canada Heparin biology.organism_classification medicine.disease Virology QR1-502 3. Good health Bacterial adhesin MenB vaccine Infectious Diseases Original Article Neisseria Invasive Neisseria meningitidis Meningitis medicine.drug |
| Zdroj: | Canadian Journal of Infectious Diseases and Medical Microbiology, Vol 26, Iss 6, Pp 299-304 (2015) The Canadian Journal of Infectious Diseases & Medical Microbiology |
| ISSN: | 1712-9532 |
| Popis: | Neisseria meningitidis can cause several invasive diseases. Serogroup distribution has been known to be related to geographical differences and, in Canada, most invasive meningococcal disease cases have been caused by serogroups B (MenB) and C. Following the introduction of a meningitis C vaccine, most cases are now caused by MenB. Characterization of invasive meningococcal disease case isolates from Atlantic Canada provides a snap shot of the molecular epidemiology, shedding light on the future of a MenB vaccine. BACKGROUND: Serogroup B Neisseria meningitidis (MenB) has always been a major cause of invasive meningococcal disease (IMD) in Canada. With the successful implementation of a meningitis C conjugate vaccine, the majority of IMD in Canada is now caused by MenB. OBJECTIVE: To investigate IMD case isolates in Atlantic Canada from 2009 to 2013. Data were analyzed to determine the potential coverage of the newly licensed MenB vaccine. METHODS: Serogroup, serotype and serosubtype antigens were determined from IMD case isolates. Clonal analysis was performed using multilocus sequence typing. The protein-based vaccine antigen genes were sequenced and the predicted peptides were investigated. RESULTS: The majority of the IMD isolates were MenB (82.5%, 33 of 40) and, in particular, sequence type (ST)-154 B:4:P1.4 was responsible for 47.5% (19 of 40) of all IMD case isolates in Atlantic Canada. Isolates of this clone expressed the PorA antigen P1.4 and possessed the nhba genes encoding for Neisseria heparin-binding antigen peptide 2, which together matched exactly with two of the four components of the new four-component meningococcal B vaccine. Nineteen MenB isolates had two antigenic matches, another five MenB and one meningitis Y isolate had one antigenic match. This provided 75.8% (25 of 33) potential coverage for MenB, or a 62.5% (25 of 40) overall potential coverage for IMD. CONCLUSION: From 2009 to 2013, IMD in Atlantic Canada was mainly caused by MenB and, in particular, the B:4:P1.4 ST-154 clone, which accounted for 47.5% of all IMD case isolates. The new four-component meningococcal B vaccine appeared to offer adequate coverage against MenB in Atlantic Canada. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|